General Information of Drug (ID: DMOX8JE)

Drug Name
L-159093 Drug Info
Synonyms CHEMBL24322; L-159093; BDBM50041969; L006880; 3-{2-Butyl-4-oxo-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,4-dihydro-quinazolin-6-yl}-1-isopropyl-1-methyl-urea
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9829012
TTD Drug ID
DMOX8JE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ANGIOTENSIN II DMLWQ27 Increase blood pressure BA04 Approved [3]
SARALASIN DMKS1DV Hypertension BA00-BA04 Approved [4]
EMA-401 DMYOUB6 Peripheral neuropathy 8C0Z Phase 2 [5]
MP-157 DM5VXWO Hypertension BA00-BA04 Phase 1 [6]
PMID25416646-Compound-Figure5-E DMYO7VH N. A. N. A. Patented [7]
Phenylpyridine derivative 3 DMDT5JI N. A. N. A. Patented [7]
1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 DMGYZQ2 N. A. N. A. Patented [7]
Fonsartan DM15LAP Hypertension BA00-BA04 Discontinued in Phase 2 [8]
L-158282 DMKSEIY N. A. N. A. Discontinued in Phase 2 [9]
TAK-591 DM25DB4 Hypertension BA00-BA04 Discontinued in Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [11]
Olmesartan medoxomil DMWBHRY High blood pressure BA00 Approved [12]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [11]
Valsartan DMREUQ6 Chronic heart failure BD1Z Approved [11]
Candesartan DMRK8OT Chronic heart failure BD1Z Approved [13]
Telmisartan DMS3GX2 Hypertension BA00-BA04 Approved [14]
ANGIOTENSIN II DMLWQ27 Increase blood pressure BA04 Approved [15]
SARALASIN DMKS1DV Hypertension BA00-BA04 Approved [16]
Tasosartan DMM13DI Hypertension BA00-BA04 Approved [17]
Eprosartan DM07K2I Hypertension BA00-BA04 Approved [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin II receptor type-1 (AGTR1) TT8DBY3 AGTR1_HUMAN Inhibitor [1]
Angiotensin II receptor type-2 (AGTR2) TTQVOEI AGTR2_HUMAN Inhibitor [2]

References

1 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
2 A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor. J Med Chem. 1993 Oct 15;36(21):3207-10.
3 The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
4 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
5 Clinical pipeline report, company report or official report of Spinifex.
6 As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard
7 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
8 Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43.
9 Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
10 Clinical pipeline report, company report or official report of Takeda (2009).
11 Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
12 Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
13 Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
14 Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
15 The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
16 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
17 Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
18 Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.